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ABSTRACT
Use of highly potent small interfering RNAs (siRNAs)
can substantially reduce dose-dependent cytotoxic
and off-target effects. We developed a genetic for-
ward approach by fusing the cytosine deaminase
gene with targets for the robust identification of
highly potent siRNAs from RNA interference (RNAi)
libraries that were directly delivered into cells via
bacterial invasion. We demonstrated that two
simple drug selection cycles performed conveni-
ently in a single container predominately enriched
two siRNAs targeting the MVP gene (siMVP) and
one siRNA targeting the egfp gene (siEGFP) in sur-
viving cells and these proved to be the most effec-
tive siRNAs reported. Furthermore, the potent
siRNAs isolated from the surviving cells possessed
noncellular toxic characteristics. Interestingly, the
length of highly potent siMVPs identified could be
as short as 16-mer, and increasing the length of
their native sequences dramatically reduced RNAi
potency. These results suggest that the current
approach can robustly discover the most potent
and nontoxic siRNAs in the surviving cells, and
thus has great potential in facilitating RNAi applica-
tions by minimizing the dose-dependent and
sequence nonspecific side effects of siRNAs.
INTRODUCTION
RNA interference (RNAi) is an evolutionarily conserved
mechanism for silencing gene expression via the sequence-
speciﬁc degradation of target RNA. In the past years,
RNAi has become a very powerful genetic tool for func-
tional genomics study, and its rapid advance has led to
the development of RNAi-based therapeutics for treating
human diseases. A prerequisite in the use of RNAi
as a reverse genetic tool or as a therapeutic is the
choice of potent and speciﬁc small interfering RNA
(siRNA) sequences. It has been reported that the applica-
tion of low doses of potent siRNAs/short hairpin RNAs
(shRNAs) in vivo greatly reduced their oﬀ-target eﬀects
and cytotoxicities (1,2), which are the two major concerns
in RNAi applications. Further studies also revealed that
low-doses of potent siRNAs/shRNAs minimized the pos-
sibility of competition with endogenous miRNA machin-
ery (2). At present, for RNAi studies most researchers use
the reported algorithms simply to design several siRNA/
shRNA sequences per target gene for synthesis (1,3,4).
However, since the RNAi mechanism is currently not
fully illustrated, it is acknowledged that the RNAi potency
of such empirically designed siRNAs is uncertain until
experimentally validated, and highly potent siRNAs,
which would be particularly valuable for therapeutics,
could not be predicted by the current design algorithms
(1,5,6). Accordingly, alternative approaches have been
made to deﬁne eﬀective siRNAs/shRNAs for RNAi. The
siRNAs as pools have been directly generated by the enzy-
matic digestion of double-stranded RNAs (dsRNAs), and
have proven eﬀective for silencing target genes (7,8).
Furthermore, eﬀective siRNAs/shRNAs could be identi-
ﬁed from RNAi libraries through high-throughput screen-
ing (5,6), or by experimental deﬁning, such as by
systematically extending the duplex length of siRNAs
beyond longer than 19–21nt (9). Here we describe a for-
ward approach for the robust selection of the most eﬀec-
tive siRNAs from RNAi libraries that were delivered
directly into an entire population of mammalian cells via
bacterial invasion. We show that instead of the usual
laborious cell-based assays of all wells in all plates, we
performed the entire process of both delivering siRNA
library and screening siRNAs in a single container
(dish), and then immediately identiﬁed the most potent
and nontoxic siRNAs from surviving cells upon drug
selection. Thus we demonstrated the potential of this
method for the robust discovery of the most suitable
siRNAs for functional genomics studies and the develop-
ment of RNAi-based therapeutics.
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The siRNA library construction
To construct a siRNA library, we ﬁrst replaced human
H1-U6 polymerase III promoter cassette in pHippy (10)
(a gift of Dr Moon, University of Washington) with the
double-promoter siRNA cassette of pFIV-H1/U6-Puro-
siRNA (System Bioscience, CA) to produce pHippy-SBI.
We digested the vector with BbsI and inserted two
annealed oligos (Sense: 50-AAAATATTAAGCTTAATA
TTC-30 and Antisense: 50-AAAAGAATATTAAGCTTA
ATA -30) into the digested pHippy-SBI vector to position
two SspI sites for blunt insertion of DNA fragments. The
modiﬁed vector designated pHippy-SspI. To construct
siRNA libraries, we PCR-ampliﬁed a 1.3kb-cDNA frag-
ment encoding the N-terminus of the major vault protein
(MVP) gene or a 700bp-cDNA fragment encoding the
egfp gene with the two speciﬁc primers for the each
gene. The ampliﬁed PCR products were partially digested
by DNase I in the presence of 1mM MnCl2. We isolated
DNA fragments ( 20–30pb) from gel, and ends-ﬁlled
with dNTPs using T4 DNA polymerase to make blunt
ends. The 50 phosphates of the ﬁlled DNA fragments
were removed with calf intestinal phosphatase. We ligated
the DNA fragments with SspI digested pHippy-SspI
vector at 168C overnight with DNA ligase, and redigested
the ligated products with SspI for 3h at 378C to destroy
the self-ligated pHippy-SspI vector. We transformed the
ligation reaction into Escherichia coli DH5a. After over-
night cultivation on plates, the library plasmid DNA was
puriﬁed and transformed into E. coli BT203 in which the
asd gene was deleted and plasmid pGBinv-hly was trans-
formed for delivery of siRNA libraries into mammalian
cells via bacterial invasion (5).
Synthesis of siRNA duplex
We chemically synthesized siRNAs (Integrated DNA
Technologies Inc.,) or synthesized them in vitro by T7
RNA polymerase using the Silencer siRNA construction
kit (Ambion).
Evaluation ofRNAi potency
For siMVPs, we constructed a pEGFP-MVP vector by
directly inserting the 1.3-kb coding sequence of the
MVP gene right after the stop codon of the egfp gene at
the HindIII site for expression of egfp-MVP hybrid tran-
scripts in cells. We transfected the synthesized siRNAs
using Lipofectamine 2000 (Invitrogen) into mammalian
cells at various concentrations in 96-well plates for
RNAi assays. We monitored the siMVP-mediated knock-
down of the expressed egfp-MVP hybrid transcript in
96-well plates (75ng/150ml) by ﬂuorescence plate reading
(Perkin Elmer Envision 2100 Multilabel Reader). We nor-
malized RNAi potency with the activity of RLuc expressed
by cotransfection of plasmid pRL-SV40 (5ng). For
siEGFPs, similarly we monitored the siEGFP-mediated
knockdown of the transfected egfp gene in cells and nor-
malized RNAi potency with the activity of RLuc as above.
We also further examined the eﬀectiveness of siMVP can-
didates with transfection of synthesized siMVPs into
HeLa cells on 12-well plates, and monitored knockdown
of the endogenous MVP genes by western blot analysis
with anti-MVP antibody.
Expression ofcytosine deaminase-target hybrid
transcript incells
To expressing the cytosine deaminase (CD)-target hybrid
transcript in cells, we inserted the 1.3-kb MVP fragment
coding the N-terminal sequence (or 700bp of the egfp
gene) into the HindIII site located right after the stop
codon of the CD gene (11) (Invivogen). We stably trans-
fected the constructs into HEK 293 cells for expression of
the CD-MVP and CD-egfp hybrid transcripts, respec-
tively, in the transfected cells.
Infection of mammalian cells withinvasive bacteria
We seeded human embryonic kidney (HEK) 293 cells
expressing the CD-target hybrid transcripts at a density
of 3.0 106 cells per dish on 100mm dish or 1.5 105
cells per well on 12-well plates in Dulbecco’s modiﬁed
eagle’s medium (DMEM) medium supplemented with
10% fetal calf serum at 378C in 5% CO2. For delivery
of siRNA libraries into cells via bacterial invasion, we
grew the library-transformed E. coli BT203 (see above)
in brain heart infusion (BHI) broth (Difco Laboratories)
containing 0.5mM DAP (Sigma), 40mg/ml of streptomy-
cin and 25mg/ml of zeromycin at 308C with shaking
for 0.5h. Then we further diluted overnight culture into
BHI-DAP medium to make OD600 0.1 and grew
them for another 2h at 308C with shaking. We collected
the bacteria by centrifugation, resuspended them at
1 107cells/ml in DMEM with 0.5mM DAP. We incu-
bated the prepared bacteria with HEK 293 cells expressing
the CD-target hybrid transcript at an m.o.i. of 20–30 for
2h at 378C. Under these conditions, the eﬃciency of bac-
terial internalization was 2–3 bacteria/cell. We washed
cells three times with serum-free DMEM and refed cells
with complete medium containing 25mg/ml of gentamicin
to kill extracellular bacteria, and added 5-ﬂuorocytosine
(FC) (Invivogen). At 48h after addition of 5FC, we tryp-
sinized the surviving cells in dish, and then collected and
reseeded them in dish for 5h to eliminate any contami-
nated dead cells. We extracted plasmid DNAs from the
reseeded cells survived from the primary drug selection,
and transformed them into E. coli DH5a by electropora-
tion for ampliﬁcation and preparation of the extracted
plasmid DNAs. Then we transformed the prepared plas-
mid DNAs into E. coli BT203 for the next cycle of bacter-
ial invasion and drug selection.
Evaluation of thecellular toxicity ofsiMVPs withcell
viability assays
We isolated siMVP-containing plasmids either directly
from the library (0-cycle) or from surviving cells in each
selection cycle at 150mM 5FC or from the dead cells that
were suspended in the medium after the ﬁrst bacterial
invasion and drug selection cycle. We transformed the
siMVP-containing plasmid DNAs by electroporation
into E. coli DH5a. We randomly selected 30 colonies
from each transformation, and reisolated the siMVP-
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vidual colonies. We transfected the prepared siMVP-con-
taining plasmid DNAs from individual colonies into HeLa
cells in triplicate for cell viability assays. For this we
seeded HeLa cells in antibiotic-free media at
0.5 10
4cells per well in a 96-well plate for 24h before
conducting transfection. We transfected cells with siRNAs
chemically synthesized or synthesized in vitro by T7 RNA
polymerase using the Silencer siRNA construction kit
(Ambion) (10nM) or the plasmid DNAs prepared as
above (0.2mg/well). We determined cell viability using
Alamar Blue (BioSource Int.) according to the manufac-
turer’s instructions. Brieﬂy, 72h after transfection, 25mlo f
Alamar Blue dye was added into each well containing cells
in 100ml of media. Cultures were then incubated for 0.5h
at 378C in a humidiﬁed atmosphere with 5% CO2. For the
purpose of this study, siRNAs were deﬁned as toxic when
the average values (mean SD) from three independent
experiments each performed in triplicate showed cell via-
bility below 75%.
RESULTS
A methodfor forwardselection of effective siRNAs
To develop a forward approach for the robust selection
of eﬀective siRNAs from an RNAi library, we fused a
target gene 30 to the gene encoding CD (11) (Figure 1),
which converts 5FC to toxic 5-ﬂuorouracil (5FU). We
directly delivered siRNA-expression libraries into
mammalian cells via integrin receptor-mediated bacterial
invasion (12). Eﬀective siRNAs in the library degrade the
CD-target hybrid transcript to prevent the conversion of
5FC to toxic 5FU. Therefore, only those cells that contain
highly potent siRNAs can survive in the presence of
5FC since toxic 5FU cannot accumulate in these cells
(Figure 1). Furthermore, instead of the laborious RNAi
assays in multiwell plates required by all reported other
methods, we simply performed the entire forward selection
process in a single container (dish), and then immediately
identiﬁed the most eﬀective and nontoxic siRNAs from
surviving cells in the container.
Selection of effective siRNAs targeting theMVP gene
We ﬁrst generated a stable cell line expressing a CD-MVP
(13) hybrid transcript. Using this cell line, we found that
without expressed siMVPs almost the entire cell popula-
tion was killed when the concentration of drug 5FC
reached >100mM (Figure 2). To identify the most
potent siMVPs, we performed the forward selection of
siRNAs with 150mM 5FC. After the second drug selection
cycle we found that two siRNAs, namely siMVP-586 and
siMVP-684 (17-mer), were signiﬁcantly enriched in surviv-
ing cells (Table 1). Following the third drug selection
cycle, these two siRNAs became further predominant as
24 and 7 of 34 siRNAs were siMVP-586 and siMVP-684,
respectively (Table 1). In addition of a number of unen-
riched siMVPs observed inconsistently in each drug selec-
tion cycle (Supplementary Table 1), there were a very few
other less-enriched siMVP sequences that were identiﬁed
in surviving cells (Figure 3 and Table 1). We chemically
synthesized siMVP-586 and siMVP-684 to evaluate their
RNAi potencies in comparison with siMVP-80 and
siMVP-381 both of which were the two most potent
siMVPs at the time identiﬁed (5). Western blot analysis
showed that siMVP-586, the mostly enriched siRNA in
the drug selection (24 of 33), knocked down the endogen-
ous cellular-MVP expression by  90% at a concentration
as low as 0.1nM (Figure 4A). The siMVP-684 also
silenced the endogenous MVP gene by  80%, similar to
siMVP-80 and siMVP-381 (Figure 4A). Using a more pre-
cise quantitative assay for silencing the egfp-MVP hybrid
transcript (5), siMVP-586 consistently exhibited the
highest inhibitory activity at all tested concentrations
(Figure 4B), further conﬁrming that siMVP-586 was the
most potent siRNA among the identiﬁed siMVPs in the
screenings.
Since siMVP-684 was a 17-mer siRNA the length of
which was much shorter than the most eﬀective conven-
tional 21-mer (14–16), we changed its native length to
examine the relative potencies. Adding one or two nucleo-
tides dramatically reduced RNAi potency (Figure 4C).
In contrast, its derivative 16-mers with one nucleotide
reduction (M16-1: 50-GAAAAGACAGCCCUGC-30;
M16-2: 50-AAAAGACAGCCCUGCA-30) retained RNAi
potency nearly as potent as siMVP-684 (M17). Interest-
ingly, adding one native nucleotide to M16-1 also substan-
tially reduced the RNAi potency of the resulting M17-1
Figure 1. Schematic of protocol for forward and robust selection of
eﬀective siRNAs in a single container. Mammalian cells are transfected
with pCMV-CD-taget gene constructs. Target genes are digested.
siRNA libraries are constructed from DNase I-digested target genes
and transformed into E. coli BT203, and delivered into cells via bacte-
rial invasion. Upon drug (5FC) selection, potent and nontoxic siRNAs
are immediately identiﬁed in surviving cells.
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whether the knocking down of MVP by the 16-mer
siRNA (M16-1) is through the Argonaut protein Ago-
2-mediated RNAi pathway(17), we examined the potency
ofthe16-mersiRNA(M16-1)inU87-MGcellsthatexpress
noor very little Ago-2 (18). While M16-1 exerted nodetect-
able silencing activity in inhibiting MVP in parental U87
cellsevenwithahighdose(5nM),transfectedexpressionof
Ago-2 in U87 completely restored its RNAi potency com-
parable to that observed in HeLa cells indicated in Figure 5
(Supplementary Figure 1). These results suggest that the
length of exogenous potent siRNAs could be shorter than
17-mer.
We performed the second independent forward selec-
tion, and found that siMVP-586 and siMVP-684 again
predominately enriched. However, reducing the concen-
tration of 5FC to 100mM enriched several additional
siMVPs (data not shown), suggesting that this approach
could also deﬁne more eﬀective siRNAs, but not the most
potent ones under conditions of low stringency.
Identification ofthe mostpotent siRNAs fromenhanced
green fluorescence protein library
The gene encoding enhanced green ﬂuorescence protein
(EGFP) has been widely used as a target for RNAi stu-
dies, and a highly potent siRNA sequence was reported
previously (9). To demonstrate the general usefulness of
this approach, we used the egfp gene as a target. As before,
we delivered siEGFP library via bacterial invasion into
mammalian cells, which stably express a CD-EGFP
hybrid transcript. After the second drug selection cycle,
siEGFP-18 (5-AAGCUGACCCUGAAGUUC-30) was
predominately enriched because 24 of 28 siRNAs were
siEGFP-18. There were a number of other unenriched
siEGFPs that were inconsistently observed in each drug
selection cycle (Supplementary Table 2). We compared its
RNAi potency with that of the two other siEGFPs.
One was a 27-nt siRNA designated as siEGFP-27, the
most eﬀective siEGFP identiﬁed at the time as it was
>100-fold more potent than the corresponding conven-
tional 21-mer siEGFP (9). The other was siEGFP-19
Figure 2. Dose-responses of cells to 5FC. HEK 293 cells stably expressing the CD-MVP hybrid transcript were transfected with pEGFP-C1 for
EGFP expression. After 24h, the pEGFP-C1 transfected cells were incubated with E. coli BT-203 that had been transformed with vector pHippy-SspI
(without siMVP library) at a bacteria-to-cell ratio (m.o.i.) of 20 at 378C for 2h. After washing, cells were re-fed with medium containing 25mg/ml of
gentamicin for overnight, and then incubated with 5FC at various concentrations. Photomicrographs of surviving cells showing EGFP-expressing
were taken 48h after addition of 5FC. Upper panel, GFP Images; lower panel, Optical Images.
Table 1. Enrichment of siMVPs in each drug selection cycle
Name Total sequenced clones Selection cycle Potency (knockdown%)
0th 1st 2nd 3rd
43 30 36 34
siMVP586 50-GGGGAAGAAUGGCUGGUCA-30 0 5 21 24 87.3
siMVP684 50-GAAAAGACAGCCCUGCA-30 0 2 5 7 77.3
siMVP857 50-UGCGUGAUUCUCGACCCUG-30 0 0 2 1 72.1
siMVP1270 50-UGCCUCCCGGGUGGAGGAG-30 0 0 3 2 75.8
The names of siMVPs were designated according to their positions in 1.3kb-MVP cDNA clone.
Only the sense strand is shown.
HeLa cells were transfected with 60ng pEGFP, 1.2ng pRLSV40 (Rluc) and 0.1nM siMVPs synthesized in vitro. Three independent assays each in
triplicate were performed. The potency of siMVPs was calculated by the ratio of EGFP/Rluc against the control of unrelated siRNA (siHB1).
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highest score (9 out of 10) according to the algorithm
(1,19). We in vitro synthesized the correspondent
siEGFP sequences and evaluated their potencies in knock-
down of the transfected EGFP reporter gene. Silencing
assays revealed that siEGFP-18 was signiﬁcantly more
potent than either siEGFP-27 or siEGFP-19 (Figure 4D).
Together, these results showed that our approach
indeed identiﬁed the most potent siRNAs from the
libraries.
The approach eliminates potential toxic siRNAs during
screening
A substantial number of siRNAs can induce sequence
unspeciﬁc cytotoxicity that also greatly correlates with
oﬀ-target eﬀects (20). Since the forward approach
described here is based on the selection of eﬀective
siRNAs from surviving cells, and toxic siRNAs can
reduce cell viability and enhance or can expedite cell
death during bacterial invasion and drug selection, it is
expected that toxic siRNAs should be preeliminated
from surviving cells during the drug selection. In this
regard, we compared the cellular toxicity of the siRNAs
isolated at each drug selection cycle with those that were
unselected or isolated from dead cells. Figure 5A shows
that while the viability of cells transfected with siMVPs
Figure 4. Evaluation of RNAi potency. (A) HeLa cells were transfected with chemically synthesized siMVPs at indicated concentrations with similar
transfection eﬃciency measured as coexpressed luciferase activities. Cell lysates were subjected to western blot analysis with anti-MVP after
transfection for 48h. (B) HeLa cells were transfected with 60ng pEGFP-MVP, 1.2ng pRLSV40 (Rluc) and chemically synthesized siMVPs at
indicated concentrations. (C) As with (B), HeLa cells were transfected with indicated concentrations of siMVP-684 derivatives synthesized
in vitro.( D) As with (B) and (C), HeLa cells were transfected with indicated concentrations of siEGFPs synthesized in vitro. Results in (B), (C)
and (D) were obtained from three independent experiments each performed in triplicate. RNAi potency of siMVPs was normalized by Rluc activity
for transfection eﬃciency against unrelated siRNA control (siHB1). Data are mean SD.
Figure 3. The positions and numbers of siMVPs identiﬁed in each
drug selection cycle. HeLa cells expressing the CD-MVP hybrid tran-
script were incubated with E. coli BT-203 containing the siMVP library
for delivery of siMVPs into cells at an m.o.i. of 20 at 378C for 2h.
After washing as before, 5FC was added to cells at 150mM concentra-
tion. At 48h after adding 5FC plasmid DNAs containing siMVPs were
extracted from surviving cells and transformed into E. coli DH5a.
About 30–40 colonies were randomly picked up from the transfor-
mants, and plasmid DNAs were reisolated from the cultures of indi-
vidual colonies for PCR ampliﬁcation of siMVPs using two
primers located the H1 and U6 promoter regions, respectively. The
sequences of siMVPs ampliﬁed from individual colonies were deter-
mined by DNA sequencing. At the meantime, plasmid DNA mixtures
were reextracted from the transformed E. coli DH5a, and directly
transformed into E. coli BT-203 for the second cycle of bacterial
invasion and forward drug selection, and so repeatedly for the third
selection cycle.
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cells transfected with siMVPs isolated from the ﬁrst-drug
selection cycle reached  85%. The viability of cells
transfected with siMVPs isolated from the second or
third selection cycles further increased ( 90%). Notably,
siMVPs derived from the dead cells caused further
decreases in cell viability ( 62%). Consistently, increasing
5FC concentration also signiﬁcantly reduced the cytotoxi-
city of siMVPs isolated from the surviving cells in the
drug selection (Supplementary Figure 2). Moreover, we
readily identiﬁed siMVPs from the dead cells with
toxicity equal to or more than that of the most toxic
siRNA (SRD5a2-3) reported (20). Further, the most
potent identiﬁed siRNAs, siM586, siM684 and
siEGFP18, consistently displayed noncytotoxic character-
istics in cell survival assays (Figure 5B). These results sug-
gest that this approach is able to eliminate toxic siRNAs
from the selected siRNAs.
DISCUSSION
The development of robust methods for the rapid identi-
ﬁcation of highly potent and nontoxic siRNAs to silence
any gene of interest has great potential not only in facil-
itating functional genomics studies, but also in applica-
tions for RNAi-based therapeutics. Use of the most
eﬀective siRNAs can reduce the possibility of competition
with endogenous miRNA machinery and the required
dose, resulting in minimizing the dose-dependent oﬀ-
target eﬀects (20,21). Thus, highly potent and nontoxic
siRNA oﬀer considerable advantages to the development
of RNAi-based therapeutics through eliminating or
decreasing the side eﬀects of siRNAs. Accordingly, we
applied a forward approach to selection the most eﬀective
and nontoxic siRNAs using the CD suicide gene in the
presence of 5FU.
Using the current approach, we could rapidly identify
the most eﬀective and nontoxic siRNAs from surviving
cells in a forward and robust selection manner. Instead
of the laboriously assaying RNAi potency of all wells in
plates as required by all other methods reported, we
simply performed the entire selection process in a
single container, and then immediately identiﬁed the
most eﬀective and nontoxic siRNAs from surviving cells
upon drug selection. Prior assay of the RNAi potency of
individual siRNAs in the screening was not required. Any
contaminating or less potent siRNAs in the primary drug
selection could be eliminated in a second or third drug
selection cycle if necessary. We examined the power of
this method for selecting the most eﬀective siRNAs
using both the MVP and the egfp genes as targets.
Using the MVP gene as a target, we identiﬁed siMVP-
586 as the most potent siMVP among siMVPs tested
after the second drug selection cycle. Using the egfp
gene as a target, we similarly found that only one
siEGFP, siEGFP-18, was predominantly enriched after
the second drug selection cycle, and that this was the
most potent among the tested siEGFPs. These results
showed that our approach indeed identiﬁed the most
potent siRNAs from the libraries. However, since the
entire RNAi library was generated by digesting the
target transcript and then isolating the digested fragments
for library construction, we could not completely exclude
other highly potent siRNAs against the target due to the
incomplete inclusion of all potential potent siRNAs in the
libraries. In addition, the speciﬁcity of the identiﬁed
siRNAs might be further examined by comparing the
results obtained from a library made from a nontarget
transcript though it is very unlikely that predominant
sequences could be consistently isolated from the nontar-
get library in the surviving cells.
Recent studies have shown that both siRNAs and
shRNAs exhibited dose-dependent cytotoxicity (2) that
Figure 5. Evaluation of siMVP cytotoxicity. (A) siMVP-containing
plasmids were isolated either directly from the library (selection
cycle 0), or from cells that survived in each selection cycle with
150mM 5FC, or from dead cells resulted in the ﬁrst cycle of bacterial
invasion and drug selection and transformed into E. coli. For toxicity
evaluation, 30 colonies were randomly selected from each transforma-
tion for reisolation of siMVP-containing plasmids. HeLa cells in 96-well
plate transfected in triplicate with siMVP-containing plasmids (0.2mg)
prepared from individual colonies. (B) HeLa cells transfected with
10nM of siRNAs synthesized in vitro. Cell survival values represent
the mean of three independent transfections each performed in
triplicate. Five highly toxic siMVPs, siMVP-28, siMVP-34, siMVP-52,
siMVP-59 and siMVP-61, were identiﬁed from dead cells (A) after
screening the transformed100 colonies. Their toxicity was compared
with most toxic SRD5a2-3 reported. Cellular viability assays in both
(A) and (B) were performed at 72-h after transfection. The dotted line
represents the 75% cell viability threshold. Data in (A) and (B) are
mean SD.
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machinery (2,22). In the current approach, all highly
potent siRNAs were isolated from the cells that survived
in drug selection. Thus, toxic siRNAs in the library should
be eliminated from surviving cells during screening
because these toxic siRNAs can reduce cell viability and
enhance and/or expedite cell death during bacterial inva-
sion and drug selection. Cellular toxicity assays showed
that cell viability was greatly increased following drug
selection (Figure 5A), and that all of the identiﬁed
potent siRNAs, such as siMVP-586, siMVP-684 and
siEGFP-18, were nontoxic (Figure 5B). In addition,
highly toxic siRNAs were readily identiﬁed from the
dead cells during the drug selection (Figure5B). Hence,
the current approach can eliminate toxic siRNAs from
those selected, resulting in robust enrichment of the
most potent and nontoxic siRNAs.
Previously studies of Drosophila melanogaster suggested
that 21-bp RNA duplexes with two-base 30 overhangs
were the most eﬀective siRNAs for gene silencing
in vitro (14,15). Reducing the RNA duplexes to 20 or
increasing the RNA duplexes to 23bp, resulted in reduce
potent (14). Interestingly, we found during screening for
eﬀective siMVPs that siMVP-684, one of the two most
potent siRNAs identiﬁed, was a 17-mer, which was
much shorter than the most eﬀective conventional
21-mer. We further examined its RNAi potency relative
to its length by systematic lengthening or shortening.
Adding one or two nucleotides dramatically reduced its
RNAi potency (Figure 4B). In contrast, reducing the
17-mer by one nucleotide to a 16-mer did not apparently
aﬀect its potency. Notably, adding back one nucleotide to
the 16-mer (M16-1) also resulted in a substantial reduction
of its RNAi potency. These results suggest that, unlike
Dicer-produced endogenous siRNAs, the length of exo-
genous potent siRNAs can very greatly, and the 16-mers
described here were the shortest and most sequence-
speciﬁc potent siMVPs so far identiﬁed, although the
functional mechanism of these short siRNAs in the
RNA-induced silencing complex (RISC) remains elusive.
The identiﬁcation of the highly potent siMVP-684 and its
two short M-16 derivatives (16-mers) further demonstrates
the power of the current forward approach for identifying
the most eﬀective and nontoxic siRNAs from libraries
though the applications of such short siRNAs could
cause more oﬀ-target eﬀects than that of conventional
longer siRNAs. Since few highly potent siRNAs were
identiﬁed by the current approach, these siRNA sequences
can be readily modiﬁed chemically for stabilization in vivo
and to eliminate their potential oﬀ-target eﬀects (23).
Hence, the current approach can eliminate toxic siRNAs
from those selected to allow the robust enrichment of the
most potent and nontoxic siRNAs, thus facilitating RNAi
applications for studies of functional genomics and for the
development of RNAi-based therapeutics.
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